HLA class I molecules consistently present internal influenza epitopes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 2, 2009, Pages 540-545

  Wahl, Angela ^a   Schafer, Fredda ^a   Bardet, Wilfried ^a   Buchli, Rico ^b   Air, Gillian M ^a   Hildebrand, William H ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Pure Protein LLC   (United States)

Author keywords

Cytotoxic T lymphocyte; Major histocompatibility complex; Mass spectrometry

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; LIGAND; MATRIX PROTEIN; VIRUS HEMAGGLUTININ; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSGENIC MOUSE; VIRUS STRAIN;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL CORE PROTEINS; VIRAL PROTEINS;

MUS MUSCULUS; ORTHOMYXOVIRIDAE;

EID: 58849154514     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811271106     Document Type: Article

References (43)

1. Yewdell J, Bennink JR, Hosaka Y (1988) Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239:637-640.
2. Potter CW, Oxford JS (1979) Determinants of immunity to influenza infection in man. Br Med Bull 35:69-75.
3. Virelizier JL (1975) Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 115:434-439.
4. Dowdle WR, Downie JC, Laver WG (1974) Inhibition of virus release by antibodies to surface antigens of influenza viruses. J Virol 13:269-275.
5. Berkhoff EG, et al. (2004) A mutation in the HLA-B*2705- restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro. J Virol 78:5216-5222.
6. Boon AC, et al. (2002) Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J Virol 76:2567-2572.
7. Voeten JT, et al. (2000) Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 74:6800-6807.
8. Boon AC, et al. (2004) Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 172:4435-4443.
9. Peters B, et al. (2005) The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 3:e91.
10. Kiepiela P, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
11. Bihl F, et al. (2006) Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 176:4094-4101.
12. Hollsberg P (2002) Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus. Scand J Immunol 55:189-195.
13. Boon AC, et al. (2002) The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 76:582-590.
14. Middleton D, Menchaca L, Rood H, Komerofsky R (2003) New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61:403-407.
15. Dong T, et al. (1996) An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. Eur J Immunol 26:335-339.
16. Bao Y, et al. (2008) The influenza virus resource at the National Center for Biotechnology Information. J Virol 82:596-601.
17. Sidney J, Peters B, Frahm N, Brander C, Sette A (2008) HLA class I supertypes: a revised and updated classification. BMC Immunol 9:1.
18. Brown DM, Roman E, Swain SL (2004) CD4 T cell responses to influenza infection. Semin Immunol 16:171-177.
19. Hikono H, et al. (2006) T-cell memory and recall responses to respiratory virus infections. Immunol Rev 211:119-132.
20. Thomas, PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48-54.
21. Wall KA, et al. (1994) A disease-related epitope of Torpedo acetylcholine receptor. Residues involved in I-Ab binding, self-nonself discrimination, and TCR antagonism. J Immunol 152:4526-4536.
22. Voeten JT, Rimmelzwaan GF, Nieuwkoop NJ, Fouchier RA, Osterhaus AD (2001) Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells. Clin Exp Immunol 125:423-431.
23. Rohrlich PS, et al. (2003) HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 15:765-772.
24. Boon AC, de Mutsert G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2006) The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity. J Virol 80:6024-6032.
25. Murphy BR, Clements ML (1989) The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 146:107-116.
26. Karzon D (1996) Cytotoxic T cells in influenza immunity. Sem Virol 7:265-271.
27. Epstein SL, Lo CY, Misplon JA, Bennink JR (1998) Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160:322-327.
28. McMurtrey CP, et al. (2008) Epitope discovery in West Nile virus infection: identification and immune recognition of viral epitopes. Proc Natl Acad Sci USA 105:2981-2986.
29. Heiny AT, et al. (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS ONE 2:e1190.
30. Man S, Ridge JP, Engelhard VH (1994) Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice. J Immunol 153:4458-4467.
31. Man S, et al. (1995) Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int Immunol 7:597-605.
32. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A (1987) Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881-882.
33. Brusic V, Petrovsky N, Zhang G, Bajic V (2002) Prediction of promiscuous peptides that bind HLA class I molecules. Immunol Cell Biol 80:280-285.
34. Berkhoff EG, et al. (2005) Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 79:11239-11246.
35. Parham P, Barnstable CJ, Bodmer WF (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A, B, C antigens. J Immunol 123:342-349.
36. Prilliman KR, Lindsey M, Zuo Y, Jackson K, Zhang Y, Hildebrand WH (1997) Large-scale production of class I bound peptides: assigning a peptide signature to HLA-B*1501. Immunogenetics 45:379-385.
37. Zhang H, Air GM (1994) Expression of functional influenza virus A polymerase proteins and template from cloned cDNAS in recombinant vaccinia virus infected cells. Biochem Biophys Res Commun 200:95-101.
38. Wahl A, Weidanz J, Hildebrand W (2006) Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Rev Proteomics 3:641-652.
39. Hickman HD, et al. (2000) C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum Immunol 61:1339-1346.
40. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567.
41. Buchli R, et al. (2005) Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201: a new tool for epitope discovery. Biochemistry 44:12491-12507.
42. Buchli R, Vangundy RS, Giberson CF, Hildebrand WH (2006) Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. J Immunol Methods 314:38-53.
43. Buchli R, et al. (2004) Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry 43:14852-14863.